Skip to content

Mindfulness based cognitive therapy versus treatment as usual in adults with attention deficit hyperactivity disorder (ADHD).

Lotte Janssen, Cornelis C. Kan, Pieter J Carpentier, Bram Sizoo, Sevket Hepark, Janneke Grutters, Rogier Donders, Jan K. Buitelaar, Anne E. M. Speckens

BMC Psychiatry September 15, 2015 DOI: 10.1186/s12888-015-0591-x (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial (protocol) Peer reviewed
Sample size 120
Population Adults with ADHD
Interventions Mindfulness Based Cognitive Therapy (MBCT) treatment as usual (TAU)
Duration Assessments at baseline and at three, six and nine months after baseline
Topics Meditation
Registration NCT02463396
Key findings The protocol proposes a multi-centre randomized controlled trial to test whether adding Mindfulness Based Cognitive Therapy to treatment as usual improves clinician-rated ADHD symptom severity and secondary outcomes in 120 adults with ADHD, compared with treatment as usual alone, alongside a cost-effectiveness analysis. No outcomes are reported.

Abstract

Adults with attention deficit hyperactivity disorder (ADHD) often present with a lifelong pattern of core symptoms that is associated with impairments of functioning in daily life. This has a substantial personal and economic impact. In clinical practice there is a high need for additional or alternative interventions for existing treatments, usually consisting of pharmacotherapy and/or psycho-education. Although previous studies show preliminary evidence for the effectiveness of mindfulness-based interventions in reducing ADHD symptoms and improving executive functioning, these studies have methodological limitations. This study will take account of these limitations and will examine the effectiveness of Mindfulness Based Cognitive Therapy (MBCT) in further detail. A multi-centre, parallel-group, randomised controlled trial will be conducted in N = 120 adults with ADHD. Patients will be randomised to MBCT in addition to treatment as usual (TAU) or TAU alone. Assessments will take place at baseline and at three, six and nine months after baseline. Primary outcome measure will be severity of ADHD symptoms rated by a blinded clinician. Secondary outcome measures will be self-reported ADHD symptoms, executive functioning, mindfulness skills, self-compassion, positive mental health and general functioning. In addition, a cost-effectiveness analysis will be conducted. This trial will offer valuable information about the clinical and cost-effectiveness of MBCT in addition to TAU compared to TAU alone in adults swith ADHD. ClinicalTrials.gov NCT02463396. Registered 8 June 2015.

Comparable studies

Other randomized controlled trials on meditation, most cited first.

Study Year Design Participants
Alterations in Brain and Immune Function Produced by Mindfulness Meditation Healthy employees in a work environment 2003 Randomized controlled trial n = 41
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Open hearts build lives: Positive emotions, induced through loving-kindness meditation, build consequential personal resources. Working adults 2008 Randomized controlled trial n = 139
Short-term meditation training improves attention and self-regulation Undergraduate Chinese students 2007 Randomized controlled trial n = 40
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics